Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darigabat - Cerevel Therapeutics

Next Previous
Drug Profile

Darigabat - Cerevel Therapeutics

Alternative Names: CVL-865; PF-06372865; PF-6372865

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics; Pfizer
  • Class Analgesics; Antiepileptic drugs; Anxiolytics; Fluorobenzenes; Heterocyclic compounds; Imidazoles; Phenyl ethers; Pyrazines; Small molecules; Sulfones
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy; Panic disorder; Seizures
  • No development reported Anxiety disorders
  • Discontinued Back pain; Generalised anxiety disorder

Most Recent Events

  • 31 Mar 2025 AbbVie completes a phase II trial in in Panic disorder in USA (PO) (NCT05941442)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Panic-disorder(In volunteers) in Netherlands (PO, Tablet)
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top